Vanda Pharmaceuticals (VNDA) Projected to Post Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.6860) per share and revenue of $55.0430 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The company had revenue of $57.22 million during the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%. On average, analysts expect Vanda Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vanda Pharmaceuticals Stock Up 0.7%

VNDA opened at $6.84 on Wednesday. The business’s fifty day simple moving average is $7.54 and its 200 day simple moving average is $6.73. Vanda Pharmaceuticals has a 52 week low of $3.81 and a 52 week high of $9.94. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01. The stock has a market cap of $411.29 million, a PE ratio of -1.83 and a beta of 0.71.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Jefferies Financial Group increased their price objective on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a research report on Wednesday, December 31st. Zacks Research downgraded shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Monday, April 20th. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. Finally, Wall Street Zen cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.90.

Insider Activity at Vanda Pharmaceuticals

In related news, SVP Timothy Williams sold 42,434 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $350,929.18. Following the sale, the senior vice president directly owned 377,450 shares of the company’s stock, valued at $3,121,511.50. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Mihael Hristos Polymeropoulos sold 156,235 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $8.17, for a total value of $1,276,439.95. Following the transaction, the chief executive officer owned 2,704,496 shares in the company, valued at approximately $22,095,732.32. This represents a 5.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 314,342 shares of company stock valued at $2,583,985 in the last quarter. 8.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mercer Global Advisors Inc. ADV lifted its stake in Vanda Pharmaceuticals by 51.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 43,829 shares of the biopharmaceutical company’s stock worth $387,000 after acquiring an additional 14,836 shares during the period. Susquehanna Portfolio Strategies LLC increased its position in Vanda Pharmaceuticals by 35.1% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 150,427 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 39,087 shares during the period. Balyasny Asset Management L.P. purchased a new position in Vanda Pharmaceuticals during the 4th quarter valued at $601,000. Schonfeld Strategic Advisors LLC bought a new position in Vanda Pharmaceuticals in the 4th quarter worth $521,000. Finally, Jain Global LLC bought a new position in Vanda Pharmaceuticals in the 4th quarter worth $94,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.